DNA C

Drug Profile

DNA C

Alternative Names: DNA-C; DNA-HIV-C; DNA-HIV-PT123 vaccine; HIV clade C DNA vaccine; HIV DNA vaccine - EuroVac; HIV DNA vaccine - EuroVacc

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EuroVacc Foundation; GENEART; University of Regensburg
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; HIV Vaccine Trials Network; International AIDS Vaccine Initiative; IPPOX Foundation; Medical Research Council; MRC/UVRI Uganda Research Unit on AIDS; National Institute of Allergy and Infectious Diseases; Novartis
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Switzerland (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top